UBC announces acquisition of ABS

United BioSource Corporation (UBC) today announced the acquisition of Abt Bio-Pharma Solutions, Inc. (ABS), a Boston, Massachusetts-based provider of health economics and outcomes research, registries and observational studies, and market access solutions to the biopharmaceutical, medical device, and diagnostics industries.

“The scientists and capabilities that we gain with ABS are an excellent fit with our strategy”

The acquisition of ABS is part of UBC's ongoing strategy to build a "best in class" portfolio of scientific and medical affairs solutions to support biopharmaceutical and medical technology companies. With this acquisition UBC further expands its industry-leading team of senior experts in comparative effectiveness and comparative value; increases its registry and observational study practices; and reinforces its commercial strategy and market access capabilities. The addition of ABS scientists and resources establishes UBC with the largest presence and operational reach in the New England biomedical corridor.

"The scientists and capabilities that we gain with ABS are an excellent fit with our strategy," said Ethan Leder, CEO of United BioSource Corporation. "We have the industry's leading roster of scientists to address product value and guide the safe and effective use of biomedical technologies. Whether we are building scientific evidence to address product value and comparative effectiveness or leveraging our expertise and technology to manage the safety risks associated with a new medicine, UBC plays a pivotal role in the development and commercialization of our clients' products."

"UBC is an ideal home for ABS," said Abt Associates Chief Executive Officer Kathleen Flanagan. "After building ABS into one of the most respected organizations in its field, we are gratified to see our colleagues join an organization that shares our values and can realize even greater potential. At UBC, there will be new resources and increased reach that translates into new opportunities for our clients to support the development and commercialization of their products."